



mEOC

A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer (mEOC)


Chief Investigator: Prof. Martin Gore, Royal Marsden Hospital
Trial Coordinator: Helen Christensen – CR UK & UCL Cancer Trials Centre

GCIG Meeting - London
17th November 2013



Trial Design – 2x2 Factorial

Randomise



*Bevacizumab can be omitted from the first cycle if chemotherapy must be started within 4 weeks of surgery

- Target accrual – 332 patients
- Opened to UK recruitment January 2010
 - 41 UK Sites – 34 patients recruited
 - 2 Finnish Sites – 0 patients recruited
- Opened to US recruitment October 2010 (GOG-0341)
 - ~150 US Sites -15 patients recruited
- UK Trial closed early to recruitment August 2013
- Provisional plan to follow UK patients until end 2014₃